Sugi Predict

Sugi Predict / Compounds / SCHEMBL14552182

SCHEMBL14552182

SCHEMBL14552182

CC(=O)N[C@H]1CC(=O)NC[C@@H](C(=O)N2CCC[C@H]2C(=O)N2CCC[C@H]2C(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC1=O

nearest known ligand 0.54

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ TSLP Q969D9 12/20 0.54
▸ MC4R P32245 7/20 0.48
▸ ACE P12821 1/20 0.46
▸ ACE2 Q9BYF1 1/20 0.46
▸ MC5R P33032 3/20 0.46
▸ MC3R P41968 3/20 0.46
▸ MC1R Q01726 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16340817 0.97 TSLP (0.53) TSLPMC4RACEACE2MC5R
SCHEMBL14552176 0.94 TSLP (0.55) TSLPMC4RACEACE2MC5R
SCHEMBL14552190 0.93 TSLP (0.53) TSLPMC4RACEACE2MC5R
SCHEMBL16340843 0.93 TSLP (0.53) TSLPMC4RACEACE2MC5R
SCHEMBL16340573 0.93 TSLP (0.53) TSLPMC4RACEACE2MC5R
SCHEMBL16340448 0.93 TSLP (0.53) TSLPMC4RACEACE2MC5R
SCHEMBL16340389 0.92 TSLP (0.53) TSLPMC4RACEACE2MC5R
SCHEMBL14552189 0.91 TSLP (0.54) TSLPMC4RMC5RMC3RMC1R
SCHEMBL16340631 0.91 TSLP (0.52) TSLPMC4RACEACE2MC5R
SCHEMBL16340501 0.90 TSLP (0.52) TSLPMC4RACEACE2MC5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130012432-A1 Peptides for Treatment of Obesity NOVO NORDISK A/S (DK) 2013-01-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130012432-A1 Peptides for Treatment of Obesity MC4R, GIPR, MC3R TSLP 177/4885MC4R 1/4885ACE 1145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.